🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against superbug strains of the pathogen, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are increasing worldwide, with estimates suggesting more than 82 million new cases per year. Especially elevated rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". Ongoing monitoring revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Secure Authorization

Zoliflodacin, marketed under the name a brand name, was cleared by the American regulatory agency in December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in concurrent days. This medication, which is also used to treat UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This approval marks a huge turning point in the therapy of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Results and Global Access

As per findings released by a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which involves an injection and a pill. The study involved hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the rights to make available and distribute the drug in many developing nations.

Doctors treating patients have voiced optimism. The availability of a one-pill regimen like this is described as a "critical tool" for managing the epidemic. This is viewed as crucial to alleviate the strain of the disease for people and to halt the transmission of untreatable gonorrhoea globally.